Tuberculosis therapeutics sales will rise through 2036, driven by active TB at 61.3% of the disease type segment in 2026, supported by persistent global TB burden and expanding access to diagnostics and treatment. The market was valued at USD 1.40 billion in 2025 and is expected to be worth USD 2.98 billion by 2036.